GlassScriptPhysician profile
Emil R Heinze
NPI 1720175052
$3,290.75
in general payments reported to CMS, 2019-2025
12 companies · $637 in 2025
The $637 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $490 · 2021: $467 · 2022: $401 · 2023: $307 · 2024: $261 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.86 |
| Education | $164.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,190.53 | 2019-2025 | Otezla, Enbrel, Otezla |
| Glaxosmithkline, LLC. | $373.76 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $302.09 | 2019-2021 | |
| Abbvie INC. | $295.45 | 2019-2025 | |
| Janssen Biotech, INC. | $240.72 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $223.07 | 2025 | |
| Pfizer INC. | $195.93 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $157.79 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $113.19 | 2024-2025 | Saphnelo |
| Ucb, INC. | $100.61 | 2023-2025 | Bimzelx, Cimzia |
| Aurinia Pharma U.S., INC. | $73.13 | 2022 | |
| Fresenius Kabi USA, LLC | $24.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emil Heinze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.